Mechanism of action of analgesics used to treat osteoarthritis pain

Rheumatic Disease Clinics of North America

Volumn 29, Issue 4, 2003, Pages 733-745

  Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CALCITONIN; COCODAMOL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; GABAERGIC RECEPTOR AFFECTING AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; TRAMADOL;

CARDIOVASCULAR DISEASE; CONSTIPATION; CONVALESCENCE; DRUG DEPENDENCE; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SODIUM RETENTION; VERTIGO; WATER RETENTION;

EID: 0142062922     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00058-9     Document Type: Review

References (38)

1. Sutherland SP, Cook SP, McCleskey EW. Chemical mediators of pain due to tissue damage and ischemia. Prog Brain Res 2000;129:21-38.
2. Fitzgerald M. The course and termination of primary afferent fibres. In: Wall PD, Melzack R, editors. Textbook of pain. 2nd edition. Edinburgh: Churchill Livingstone; 1989. p. 46-62.
3. Radhakrishnan V, Henry JL. Electrophysiology of neuropeptides in the sensory spinal cord. In: Nyberg F, Sharma HS, Wiesenfeld-Hallin Z, editors. Neuropeptides in the spinal cord. Amsterdam: Elsevier; 1995. p. 175-95.
4. Fields HL. Pain. New York: McGraw-Hill; 1987.
5. Schnitzler A, Ploner M. Neurophysiology and functional neuroanatomy of pain perception. J Clin Neurophys 2000;17(6):592-603.
6. McGrath PA. Psychological aspects of pain perception. Archs Oral Biol 1994;39(Suppl): 55S-62S.
7. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66(6):355-474.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231(25):232-5.
9. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971;231(25):235-7.
10. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous system. Science 1973;179(77): 1011-4.
11. 3H-etorphine to rat brain homogenate. Proc Natl Acad Sci USA 1973;70(7):1947-9.
12. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane. Acta Pharmacol Toxicol 1973;32(3):317-20.
13. Raffa RB, Friderichs E. The basic science aspects of tramadol hydrochloride. Pain Revs 1996;3: 249-71.
14. Ferreira SH. Peripheral analgesic sites of action of antiinflammatory drugs. Int J Clin Pract 2002; 128(Suppl):2-10.
15. Tetzlaff JE. The pharmacology of local anesthetics. Anesthesiol Clin N Am 2000;18(2):217-33.
16. Björkman R. Central antinociceptive effects of non-steroidal antiinflammatory drugs and paracetamol. Acta Anaesthesiol Scand 1995;39(Suppl 103):2-44.
17. Walker JS. NSAID: an update on their analgesic effects. Clin Exper Pharmacol Physiol 1995; 22(11):855-60.
18. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
19. Pascucci RA. Use of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications. J Am Osteopath Assoc 2002;102(9):487-9.
20. Vane JR, Botting RM. A better understanding of antiinflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Advs Prostaglandin, Thromboxane, & Leukotriene Res 1995;23:41-8.
21. Scheiman JM. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. Am J Managed Care 2002;8(Suppl 17):S518-28.
22. Watson S, Arkinstall S. The G-protein linked receptor facts book. London: Academic Press; 1994.
23. Carvey PM. Drug action in the central nervous system. New York: Oxford University Press; 1998.
24. Lee CR, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46(2):313-40.
25. Cicero TJ, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH. A post-marketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999;57(1):7-22.
26. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240(5381):410-1.
27. Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 1999;96(6):3275-80.
28. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99(21):13926-31.
29. 3 receptors. Neuroreport 1995;6(11):1546-8.
30. 3 receptors: in vivo and in vitro evidence. J Pharmacol Exp Ther 1996;278(1):8-14.
31. Raffa RB, Stone Jr DJ, Tallarida RJ. Discovery of " self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther 2000;295(1):291-4.
32. Raffa RB, Stone Jr DJ, Tallarida RJ. Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. Eur J Pharmacol 2001;412(2):R1-2.
33. Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001;26(4):257-64.
34. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5(1):27-32.
35. Anonymous. Recommendations for the medical management of osteoarthritis of the hip and knee. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43 (9):1905-15.
36. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci 1996;58(2):PL23-8.
37. Tallarida RJ. Drug synergism and dose-effect data analysis. Boca Raton: Chapman & Hall/CRC; 2000.
38. Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT. Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Science 2003;424:316-20.